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Volume 54, Number 3 Abstracts 911Arterial Stiffness Predicts Cardiovascular Outcome in a Low-to-
Moderate Cardiovascular Risk Population: the EDIVA (Estudo de
DIstensibilidade Vascular) Project
Maldonado J, Pereira T, Polonia J, and participants in the EDIVA Project. J
Hypertension 2011;29:669-75.
Conclusion: Elevated pulse wave velocity (PVW) measurements are a
risk factor for major adverse cardiovascular events.
Summary: PWV measurements are used to measure aortic distensibil-
ity, a measure of aortic stiffness. More distensible aortas are less stiff than less
distensible aortas. PWV measurements are increased in less distensible
aortas. Decreased distensibility of the aorta may be a marker of atheroscle-
rosis and therefore patients with decreased aortic distensibility may be at
increased cardiovascular risk. This study determined the relationship be-
tween PWV measurements and long-term cardiovascular risk in a general
population. PWV measurements were based on distance/time ratio in m/s
with the pulse wave measured in the right carotid and right femoral artery.
Normal PWV measurements were defined statistically according to the 95th
percentile adjusted for sex and age calculated from a sample of 668 individ-
uals with low cardiovascular risk and a mean age of 39.73  15.6 years.
The study subjects of this report included 2200 Portuguese nationals
(1290 men) who were a mean age of 46.33  13.76 years (range, 18-91
years). Study subjects underwent annual PWV measurements and were
followed up for major adverse cardiovascular events (MACEs)—death,
stroke, myocardial infarction, unstable angina, peripheral arterial disease,
revascularization, or renal failure. Mean follow up was 21.42 10.8 months
in the study subjects, and there were 47 nonfatal MACEs (2.1%). PWV
measurements were higher in individuals with events then in those without
events (11.6 2.13 vs 10.01 2.01 m/s, respectively, P .001). Using the
predefined criteria for normal indicated above, the authors divided their
study population into two groups, those with normal PWVs (PWV 95th
percentile) and those with increased PWVs (PWV 95th percentile). The
cumulative event-free survival at 2 years was 99.3% in the normal PWV
group and 95% in the high PWV group. Hazard ratio for MACE in the high
PWV group was 9.9 (95% CI, 5.08-19.6, P  .001). When adjusted for
other risk factors, the hazard ratio for MACE in the patients with high PWV
measurements was 4.8 (95% CI, 2.4-9.9, P  .001).
Comment: Previous investigation has shown carotid femoral PWV is
an excellent indicator of aortic stiffness and is related to cardiovascular
mortality and morbidity in patients with diabetes, hypertension, or renal
failure (Blacher J et al, Circulation 1999;99:2434-9; and Laurent S, Hyper-
tension 2002;37:1236-41). The authors hope to convince primary-care
physicians that PWV assessment can be useful in a therapeutic approach to
modification of cardiovascular risk. Additional work, however, will clearly be
required demonstrating modification of cardiovascular risk based on an
assessment of PWV measurements results in decreased clinical events.
Aspirin plus Clopidogrel Versus Aspirin Alone After Coronary Artery
Bypass Grafting: The Clopidogrel After Surgery for Coronary Artery
Disease (CASCADE) Trial
Kulik A, Le May MR, Voisine P, et al. Circulation 2010;122:2680-7.
Conclusion: Aspirin plus clopidogrel has no added benefit compared
with aspirin alone in reducing saphenous vein graft intimal hyperplasia 1 year
after coronary artery bypass grafting (CABG).
Summary: Intimal hyperplasia is a primary means of saphenous vein
graft failure in both the coronary and peripheral circulations. This process is
in part platelet-mediated. Clopidogrel has been shown to inhibit intimal
proliferation and smooth muscle hyperplasia in both animal models and in in
vitro experiments. Aspirin alone does not inhibit intimal hyperplasia (Her-
bert JM, Thromb Haemost 1998;80:512-8). This was the first study to
determine whether clopidogrel inhibited saphenous vein graft intimal hy-
perplasia or improved angiographic graft patency after saphenous vein
grafting. This was a double-blind placebo controlled phase 2 clinical trial to
evaluate whether the addition of clopidogrel to aspirin inhibited the devel-
opment of saphenous vein graft disease after CABG.
There were 113 patients undergoing CABG who were randomized to
receive 162 mg of aspirin plus 75 mg of clopidogrel daily vs 162 mg of
aspirin plus placebo daily for 1 year. The primary outcome was saphenous
vein graft intimal hyperplasia (mean intimal area) determined by intravascu-
lar ultrasound imaging at 1 year. Secondary outcomes included major
bleeding, graft patency, and major adverse cardiovascular events. At 1-year,
intravascular ultrasound imaging and coronary angiography were performed
in 92 patients (81.4%). Saphenous vein graft intimal area did not differ
significantly between the aspirin-clopidogrel vs aspirin-placebo (4.1 2.0 vs
4.5  2.1 mm2, P  .44) groups. One-year graft patency was 95.2% in the
aspirin-clopidogrel group compared with 95.5% in the aspirin-placebo
group (P  .90). Saphenous vein graft patency was 94.3% in the aspirin-
clopidogrel group vs 93.2% in the aspirin-placebo group (P  .69). At 1
year, freedom from major adverse cardiovascular events was 92.9% 3.4% in
the aspirin-clopidogrel group vs 91.1% 3.8% in the aspirin-placebo group
(P  .76). Major bleeding was also similar at 1 year (1.8% in aspirin-
clopidogrel vs 0% in aspirin-placebo; P  .50).
a
EComment: The combination of clopidogrel and aspirin improves
utcomes compared with aspirin alone in patients who undergo percutane-
us coronary interventions. The CURE trial demonstrated dual antiplatelet
herapy reduced adverse outcomes in patients presenting with acute coro-
ary syndrome who ultimately underwent CABG. Benefit, however, ap-
eared to be primarily ascribed to the preoperative period. The coronary and
eripheral circulations are obviously different, but the intimal hyperplasia
rocess that affects saphenous vein grafts seems similar in the two circula-
ions. This study does not provide evidence that the addition of clopidogrel
o aspirin reduces intimal hyperplasia or improves graft patency.
arly Diagnosis of Intestinal Ischemia Using Urinary and Plasma Fatty
cid Binding Proteins
huijls G, van Wijck K, Grootjans J, et al. Ann Surg 2011;253:302-8.
Conclusion: Early diagnosis of intestinal ischemia can be facilitated by
n analysis of plasma for urinary fatty acid-binding proteins (FABP) as well as
rinary ileal bile acid-binding proteins.
Summary:Diagnosis of intestinal ischemia is difficult. Clinical signs are
onspecific and early diagnosis is crucial. A 24-hour delay in diagnosis
ecreases survival rates by 20% (Oldenburg et al, Arch Intern Med
004;164:1054-62). FABPs are small cytosolic proteins that are released
hen enterocyte membrane integrity is lost. They are released into the
irculation and cleared by the kidney, allowing for an analysis of both plasma
nd urinary levels. Preliminary work has suggested increased levels of FABPs
ay be markers of intestinal ischemia. The authors sought to answer the
uestion of whether circulating urinary FABP levels can distinguish patients
ith intestinal ischemia from patients without intestinal ischemia where
cute intestinal ischemia was initially suspected. This study included 50
onsecutive patients with suspected intestinal ischemia whose blood and
rine samples were analyzed at the time of presentation or with symptoms
uggestive of the diagnosis. Plasma and urinary concentrations of intestinal
ABP (I-FABP), liver FABP (L-FABP), and ileal bile acid binding protein
I-BABP) were measured. There were 22 patients with suspected intestinal
schemia among the 50 originally screened who were ultimately diagnosed
ith intestinal ischemia and 24 who were diagnosed with other diseases. The
our remaining patients were excluded from further analysis because of
reexisting intestinal damage from a recent colon operation. Plasma concen-
rations of I-FABP and L-FABP and urinary concentrations of all three
arkers were higher in patients with an ultimate diagnosis of intestinal
schemia than in those patients in whom intestinal ischemia was originally
uspected but who ultimately had an alternative diagnosis: plasma I-FABP,
53 vs 109 pg/mL (P  .02); plasma L-FABP, 117 vs 25 ng/mL (P 
006); urine I-FABP, 3377 vs 115 pg/mL (P .001); urine L-FABP, 1199
s 37 ng/mL (P  .004); urine I-BABP, 48.6 vs 0.6 ng/mL (P  .002).
here was a trend to higher plasma I-BABP levels when the ileum was
nvolved (18.4 ng/mL vs 2.9 ng/mL, P  .05).
Comment: Urinary FABP levels resulted in a markedly increased
ositive post-test probability of ischemia and a clearly decreased negative
ost-test probability of intestinal ischemia. The data suggest urinary levels of
ABP may be the long-awaited laboratory diagnosis providing confirmation
f intestinal ischemia.
redictors of Abdominal Aortic Aneurysm Sac Enlargement After
ndovascular Repair
hanzer A, Greenberg RK, Hevelone N, et al. Circulation 2011;123:
848-55.
Conclusion: In the Unites States compliance with endovascular aneu-
ysm repair (EVAR) device guidelines is low. Rates of post-EVAR aneurysm
ac enlargement are high.
Summary: Companies marketing EVAR devices measure technical
actors such as delivery accuracy, sealing ability, and fixation strength in the
aboratory. These measurements are used to generate instructions for use
IFU) that are packaged with each EVAR device sold in the United States.
he randomized trials comparing EVAR with open aneurysm repair have
sed EVAR devices in accordance with IFUs. Many physicians may perform
VAR without adherence to IFUs. It is unknown how often EVAR is
erformed outside the IFU for the device and longer-term results of EVAR
erformed outside IFUs are unknown. However, a significant portion of late
eaths after EVAR are due to aneurysm rupture (De Bruin JL et al, N Engl
Med 2010;362;1881-9, and Wyss TR, Ann Surg 2010;252;805-12) and
neurysm rupture after EVAR is linked with aneurysm sac enlargement. The
uthors sought to determine compliance with IFUs in EVAR placement
ver the last decade and to determine relationships between anatomic
haracteristics at baseline of aorta and iliac arteries and the subsequent
ncidence of aortic aneurysm sac enlargement after EVAR. The authors
xamined patients undergoing EVAR between January 1, 1999, and De-
ember 31, 2008, using a medical imaging repository at M2S, Inc. (West
ebanon, NH). The deidentified data on all patients in the prospectively
cquired M2S database was used for those who underwent a CT scan before
VAR and had at least one CT scan after EVAR between 1999 and 2008 in
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September 2011912 Abstractsthe United States. Patients were excluded if they underwent an EVAR in the
context of premarketing or postmarketing studies in which M2S served as a
core imaging laboratory. Preoperative aorta iliac anatomic characteristics
were reviewed for each patient. The specific endovascular device implanted
was not available from this database. Morphologic measurements were
therefore compared with the most liberal and most conservative published
anatomic guidelines stated in manufacturer’s IFUs. Primary outcome was
post-EVAR aneurysm sac enlargement5 mm. There were 10,228 patients
included in the database and used for the study. Of these, 59% had a
maximum abdominal aortic aneurysm diameter below the 55-mm threshold
at which intervention is recommended over surveillance. Forty-two percent
of patients had anatomy that met the most conservative definition of IFUs
and 69% met the most liberal definition of device IFUs. The 5-year post-
EVAR rate of AAA sac enlargement was 41%. Independent predictors of
AAA sac enlargement included age 80 years, endoleak, aortic neck diam-
eter 28 mm, aortic neck angle 60°, and common iliac artery diameter
20 mm.
Comment: Some physicians placing EVAR devices may be acting in
what some could consider an irresponsible fashion. In this study, most
EVAR devices were placed in abdominal aortic aneurysms that were below
the threshold for intervention justified by randomized trials. Even with the
most liberal definition of IFUs almost one-third of devices were placed
outside manufacturer’s recommendations, and in this database, 40% of
aortas treated with EVAR had aneurysm sac enlargement at 5 years. The data
are disturbing and raise significant questions about aneurysm treatment in
the United States and about long-term risk of aneurysm rupture in patients
treated with EVAR in the United States. Physicians placing EVAR devices
need to do better job of policing themselves. If not, one can be sure someone
else will! One can only speculate that it won’t take long for the malpractice
attorneys to stumble on to this.
Risk of Surgery Following Recent Myocardial Infarction
Livhits M, Ko CY, Leonardi MJ, et al. Ann Surg 2011;253:857-64.
Conclusion: A recent myocardial infarction (MI) is a significant risk
factor for postoperative MI and mortality. When possible, delaying the
operation for 8 weeks after MI and medical optimization should be consid-
ered before elective surgery.
Summary: No large contemporary studies have assessed the risk of
surgery for patients with a history of recent MI. Advances in reducing
operative complications may reduce postoperative morbidity and mortality
in patients with cardiac risk factors. Such advances, in fact, may also reduce
t
Mhe risk of a subsequent MI in a patient with a recent MI undergoing elective
urgery. The authors examined five common noncardiac operations (hip
urgery, colectomy, cholecystectomy, abdominal aortic aneurysm repair,
nd amputation) to determine whether a recent MI remains a risk factor for
oor postoperative outcomes and whether that risk can be lessened by time
lapsed from the MI. The authors used the California Patient Discharge
atabase to retrospectively analyze patients undergoing the five index pro-
edures from 1999 to 2004 (n 563,842). They evaluated the incidence of
ostoperative 30-day MI, 30-day mortality, and 1-year mortality and com-
ared these values for patients with or without a recent MI. Relative risk
RR) with 95% confidence intervals were estimated using boot strapping
ith 1000 repetitions.
The postoperative MI rate for the recent MI cohort decreased substan-
ially as the length of time between MI and the operation increased: 0-30
ays, 32.8%; 31-60 days, 18.7%; 61-90 days, 8.4%; and 91-180 days, 5.9%.
he 30-day mortality also decreased as length from recent MI increased:
-30 days, 14.2%; 31-60 days, 11.5%; 61-90 days, 10.5%; and 91-180 days,
.9%. An MI occurring 30 days of an operation was associated with a
igher risk of postoperative MI (RR range, 9.98-44.29 for the 5 proce-
ures), 30-day mortality (RR range, 1.83-3.84), and 1-year mortality (RR
ange, 1.56-3.14). The 30-day mortality rate was 10.3% in patients under-
oing abdominal aortic aneurysm repair30 days of a recent MI and 17.2%
or patients undergoing amputation 30 days of a recent MI (14.3% for
elow knee amputation and 23.0% for above knee amputation). The 1-year
ortality for patients undergoing below knee amputation30 days of a MI
as 47.0% and 1-year mortality for patients undergoing above knee ampu-
ation 30 days of a MI was 67.5%. Despite these numbers, the risk of
ostoperative MI for patients with MI 30 days of operation was actually
ower in patients undergoing abdominal aortic aneurysm repair or amputa-
ion compared with those undergoing a nonvascular procedure. Patients
ndergoing abdominal aortic aneurysm repair or amputation also appeared
o have a lower rate of 30-day and 1-year mortality compared with patients
ndergoing the nonvascular procedures.
Comment: A recent MI remains a significant risk factor for postoper-
tive MI and death. Surprisingly, the increased risk of postoperative MI after
recent MI appears greater for nonvascular operations. It would be useful in
uture studies to examine clinical factors such as -blocker therapy, blood
ressure control, and statin use and their effects on the postoperative MI rate
n patients undergoing elective surgery after a recent MI. It is best to wait as
ong as possible after a MI before proceeding with elective surgery. Most of
he benefit, however, appears to be achieved after waiting 2 months after a
I.
